The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Nicole B. Harrold, BS, Manager, Continuing Education and Grants
Ms. Harrold has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Daly MB, Axilbund JE, Buys SS et al.. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian.Version 1, 2013. Available at: NCCN.org. Accessed April 10, 2013.
Chompret A, Abel A, Stoppa-Lyonnet D et al.. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001;38:43–47.
Villani A, Tabori U, Schiffman J et al.. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011;12:559–567.
Antoniou A, Pharoah PD, Narod S et al.. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–1130.
Ambrosone CB. The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer. Breast Cancer Res 2007;9:114.
Gonzalez KD, Noltner KA, Buzin CH et al.. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27:1250–1256.
Tinat J, Bougeard G, Baert-Desurmont S et al.. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009;27:e108–109; author reply e110.
Chompret A, Brugieres L, Ronsin M et al.. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000;82:1932–1937.
Olivier M, Goldgar DE, Sodha N et al.. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003;63:6643–6650.
Hisada M, Garber JE, Fung CY et al.. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606–611.
Masciari S, Dillon DA, Rath M et al.. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 2012;133:1125–1130.
Wilson JR, Bateman AC, Hanson H et al.. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010;47:771–774.
Melhem-Bertrandt A, Bojadzieva J, Ready KJ et al.. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2012;118:908–913.
Trkova M, Prochazkova K, Krutilkova V et al.. Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age. Cancer 2007;110:694–702.
Tabori U, Malkin D. Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res 2008;68:2053–2057.
Tabori U, Nanda S, Druker H et al.. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007;67:1415–1418.
Bougeard G, Baert-Desurmont S, Tournier I et al.. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006;43:531–533.
Marcel V, Palmero EI, Falagan-Lotsch P et al.. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet 2009;46:766–772.
Gomes MC, Kotsopoulos J, de Almeida GL et al.. The R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 2012;10:3.
Ashton-Prolla P, Osorio C, Koehler-Santos P et al.. Contribution of TP53 p.R337H mutation to breast cancer prevalence in Brazil. Presented at the 2012 ASCO Annual Meeting; June 1-5, 2012; Chicago, Illinois.
Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001;96:238–242.
Henry E, Villalobos V, Million L et al.. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw 2012;10:939–942.
Ford JM, Kastan MB. DNA damage response pathways and cancer. In: Abeloff M, ed. Abeloff’s Clinical Oncology, 4th ed. Philadelphia, PA: Churchill Livingstone; 2007:139–152.